Clopidogrel plus aspirin significantly reduced the risk of compound vascular events (HR 0.47) compared to aspirin alone during hospitalization in patients with acute mild-to-moderate ischemic stroke.
Cohort (n=506)
Yes
Does clopidogrel and aspirin combination therapy reduce compound vascular events in patients with acute mild-to-moderate ischemic stroke during hospitalization?
Dual antiplatelet therapy with clopidogrel and aspirin, combined with high-intensity statins, significantly reduces the risk of compound vascular events without increasing hemorrhage risk during hospitalization for acute mild-to-moderate ischemic stroke.
Effect estimate: HR 0.47 (95% CI 0.25-0.87)
Absolute Event Rate: 7.2% vs 13.7%
p-value: p=0.017
OBJECTIVE: Subsequent vascular events are common after acute ischemic stroke during hospitalization. This study aimed to analyze the effectiveness of combination therapy with clopidogrel and aspirin among mild-to-moderate ischemic stroke patients treated within 72 h on the basis of a high-intensity dose of statins. METHODS: In a retrospective and multicenter cohort study, acute (within 72 h of onset) mild-to-moderate stroke patients were divided into aspirin and clopidogrel-aspirin groups on the basis of a high-intensity dose of statin therapy. The primary outcome was compound vascular events during hospitalization. Cox's proportional hazards model was used to assess differences, with the study center as a random effect. RESULTS: Among the 506 patients meeting the eligibility criteria, all subjects received a high-intensity dose of statins, including 20 mg rosuvastatin or 40 mg atorvastatin while in the hospital. In an unadjusted analysis, compound vascular events occurred in 7.2% of patients in the clopidogrel-aspirin group compared with 13.7% of those in the aspirin group (p = 0.022). In a Cox proportional hazards regression analysis, clopidogrel-aspirin was associated with a lower risk of compound vascular events (hazard ratio 95% CI, 0.47 0.25-0.87; p = 0.017) and ischemic vascular events (p = 0.008). Moderate and severe hemorrhage occurred in four patients (1.07%) in the clopidogrel-aspirin group and three patients (2.30%) in the aspirin group (p = 0.626). INTERPRETATION: In this study based on high-intensity statin therapy, clopidogrel-aspirin reduced the risk of compound vascular events and did not increase the risk of hemorrhage during patients' hospitalization after mild-to-moderate ischemic stroke within 72 h.
Fan et al. (Sat,) conducted a cohort in Acute mild-to-moderate ischemic stroke (n=506). Clopidogrel plus aspirin vs. Aspirin monotherapy (100-300 mg on day 1, then 100 mg/day) was evaluated on Compound vascular events (composite of ischemic stroke, TIA, myocardial infarction, and moderate to severe bleeding events) (HR 0.47, 95% CI 0.25-0.87, p=0.017). Clopidogrel plus aspirin significantly reduced the risk of compound vascular events (HR 0.47) compared to aspirin alone during hospitalization in patients with acute mild-to-moderate ischemic stroke.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: